Bixuan DongFollowNovo Nordisk (China)1 paperOpenAlexPapersDiabetes TherapyHuman trial·29 SepCombined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc AnalysisSGLT2 inhibitors
Diabetes TherapyHuman trial·29 SepCombined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc AnalysisSGLT2 inhibitors